News
2018.03.30
Comprehensive Commercialization Rights Granted to Neopharma on the Pharmaceuticals Containing 5-ALA
SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that SBI Pharmaceuticals has granted the comprehensive commercialization rights on the pharmaceuticals containing 5-ALA including “ALAGLIO Divided Granules 1.5g” in the territory of MENA *2 and India to neopharma Japan Co., Ltd. (Head office: Chiyoda-ku, Tokyo; Representative Director: Satofumi Kawata; “neopharma Japan”), a subsidiary of neopharma LLC *3, a company of the United Arab Emirates (UAE) engaged in production and marketing of pharmaceuticals.
See more